US FDA extends review period for Eisai's eribulin
This article was originally published in Scrip
Executive Summary
The US FDA has extended by three months the NDA review period for Eisai's anticancer product eribulin mesylate. The agency now expects to complete its priority review for use in locally advanced or metastatic breast cancer on or before 30 December.